Clinical Trial

"QUAD SHOT" Radiotherapy With Pembrolizumab in Patients With Recurrent Head & Neck Cancer

Study acronym: QUADSHOT
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to test the safety of palliative "QUAD SHOT" radiotherapy combined with pembrolizumab and evaluate the effects of the combination treatment patients with recurrent cancer of head and neck.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2020-05-01; most recent amendment 2026-05-07.
Status change: Recruiting → Active, Not Recruiting 2025-07-23
Status change: Not Yet Recruiting → Recruiting 2020-12-18
Trial Details
NCT Number NCT04373642
Lead Sponsor University of Oklahoma
Conditions Head and Neck Cancer
Enrollment 30 participants
Start Date 2020-12-23
Primary Completion 2025-10-14 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2026-05-11